The source of the conversation is Katherine's New York Times best seller - Bottle of Lies.  From corporate malfeasance to efficacy of bioequivalence - this discussion covers a sweeping subject.  This podcast has real relevance for health insurers, benefits advisors and employers who implement, manage and deliver drug insurance  . The time for this conversation is past due.   At the end of the day it's about the patients who rely on these drugs daily - either to sustain quality of life or perhaps even to sustain life.  On any given day each of us is either a patient or could become one!  Do we know how these dugs are manufactured, how they work and what goes into them?